PD Dr. Daniel Merk
Research in our group addresses nuclear receptors as (potential) drug targets. These proteins act as ligand-activated transcription factors and translate small molecule ligand signals into adaptions in gene expression. We study the medicinal chemistry of nuclear receptor ligands and develop nuclear receptor modulators as tool compounds. Therein, we focus on nuclear receptors involved in neuro-protection and neurodegeneration.
Please use the following link for a complete list of publications: